Jazz Pharmaceuticals PLC $JAZZ is Estuary Capital Management LP's 5th Largest Position

Key Points

• Estuary Capital Management LP increased its holdings in Jazz Pharmaceuticals by 33.2%, owning a total of 309,750 shares after purchasing 77,233 additional shares in the 1st quarter.
• Analysts have set a consensus price target of $178.67 for Jazz Pharmaceuticals, with recommendations varying from "hold" to "buy" from several investment firms.
• Jazz Pharmaceuticals reported a negative earnings per share of ($8.25) for the last quarter, missing the consensus estimate, while also indicating a revenue increase of 2.1% year-over-year.

Estuary Capital Management LP lifted its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 33.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 309,750 shares of the specialty pharmaceutical company's stock after acquiring an additional 77,233 shares during the period. Jazz Pharmaceuticals accounts for approximately 9.3% of Estuary Capital Management LP's holdings, making the stock its 5th biggest holding. Estuary Capital Management LP owned 0.50% of Jazz Pharmaceuticals worth $38,455,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after acquiring an additional 119 shares during the last quarter. Picton Mahoney Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. Finally, Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after acquiring an additional 161 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JAZZ. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Morgan Stanley raised their price objective on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. The Goldman Sachs Group raised their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research note on Friday, August 29th. Royal Bank Of Canada raised their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $178.67.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 0.3%

JAZZ stock traded up $0.35 during trading on Monday, hitting $129.85. 522,708 shares of the company's stock traded hands, compared to its average volume of 944,438. The firm has a market capitalization of $7.88 billion, a P/E ratio of -19.29, a PEG ratio of 8.03 and a beta of 0.24. The business has a fifty day simple moving average of $116.68 and a two-hundred day simple moving average of $116.77. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.